The Price of Getting Sick in America
Two patients. Two failures. A decades-long crisis that demands real answers.
When a TV Drama Tells the Truth
Some stories land harder than others. In a recent episode of The Pitt, a drama set inside a Pittsburgh emergency department, two patient storylines unfold quietly alongside each other. Neither ends in a dramatic courtroom revelation or a heroic last-minute save. Both end with something more unsettling: the system simply failing people who needed it.
The first patient is diabetic. He comes in sick, is evaluated, and receives a clear recommendation from his care team. He should stay. He knows this. He leaves anyway. He leaves because the fear of the bill that will follow him home is more immediate than the abstract danger of worsening illness. He has done the arithmetic. He knows what hospitalization costs, what his insurance covers, and what the gap will look like. He chooses the financial risk over the medical one.
He comes back. When he does, he is far sicker than when he first walked through the doors. The care he now requires is far more intensive, far more costly, and far more uncertain than what he would have needed had he stayed the first time. A manageable situation became a crisis. A crisis that was entirely predictable. Ironically, after his health disaster, he now qualifies for Medicaid and Medicare.
He did not leave because he was reckless. He left because the bill frightened him more than the diagnosis.
The second patient is the son of a hairdresser. She lost his Medicaid coverage. Not because he became ineligible. Not because she earned more money or changed her circumstances in any way that should have ended her enrollment. She lost it because the administrative machinery that governs Medicaid renewals failed her. Paperwork. Missed notices. A process that asks vulnerable people to navigate complexity that would challenge a trained benefits attorney. She delayed care while trying to sort out a bureaucratic problem she never should have faced. By the time she arrives in the ED, her son is in crisis.
These are fictional characters. Their stories are not fictional experiences. Millions of Americans make versions of these calculations every year. They skip doses, delay appointments, and leave hospitals early. They lose coverage not because they age out or earn more, but because the paperwork won. The question their stories raise is one the American healthcare system has been asked for decades and has not yet answered: why does care cost this much, and what are we prepared to do about it?
A Pricing Problem, Not a Usage Problem
The temptation is to pin the American healthcare cost crisis to a specific law or a specific decade. The Affordable Care Act. The HITECH Act. Managed care in the 1990s. Each of these moments shaped the system we have today. None of them created the underlying problem.
The United States has spent more per capita on healthcare than any other high-income nation for at least four decades. The gap has widened, not narrowed. Americans do not visit the doctor more often than citizens of peer nations. They do not spend more nights in hospitals on average. They pay dramatically more for each unit of service they receive.
A hip replacement in the United States costs roughly three to four times what the same procedure costs in Germany. An MRI that runs $1,400 here runs under $200 in Japan. A month of insulin that costs $300 in the US costs under $30 in Canada. The procedures are the same. The drugs are the same. The prices are not.
~$13,000 US per-capita health spending (2024 est.)
~$6,000 Average per-capita spending among comparable nations
18% Share of US GDP devoted to healthcare
Several forces sustain those prices. Hospital consolidation across the country has eroded competitive pressure in regional markets. Health systems with dominant market positions can negotiate rates that smaller, fragmented systems cannot. The result is higher prices for insurers, and eventually higher premiums and out-of-pocket costs for patients.
Administrative complexity adds another layer of cost that is nearly unique to American healthcare. Estimates consistently suggest that close to 30 cents of every healthcare dollar goes to billing, coding, prior authorization, credentialing, and claims processing rather than to any form of care. The hairdresser in The Pitt lost her coverage navigating a narrow slice of that apparatus.
Pharmaceutical pricing sits in its own category. For decades, the United States permitted drug manufacturers to set launch prices without government negotiation. A drug approved for sale in France, Germany, and Canada are five to ten times less expensive than in the United States. The same molecule. The same trials. The same FDA approval. A very different price.
Bending the Cost Curve, and What Bent It Back
The phrase "bending the cost curve" entered serious healthcare policy conversation in the early 2000s. It became a central promise of the Affordable Care Act. For a period, there was genuine reason for optimism. Between roughly 2010 and 2015, the growth rate of healthcare spending slowed measurably. Economists debated the causes: the lingering effects of the 2008 recession suppressing utilization, early value-based payment experiments, modest movement toward care coordination.
The HITECH Act of 2009 poured billions into accelerating the adoption of electronic health records. The underlying theory was sound. Digitized patient data should enable better coordination, reduce redundant testing, and help clinicians make better decisions. What happened in practice was more complicated. EHR adoption surged. Administrative burden surged alongside it. Physicians who had hoped to spend more time with patients found themselves spending more hours on documentation. The technology that was supposed to reduce friction added friction of a different kind.
The ACA's structural interventions were more promising. Accountable care organizations, bundled payments for procedures like joint replacements and cardiac care, and the gradual shift toward value-based reimbursement all represented genuine attempts to rewire a fee-for-service system that rewards volume regardless of outcome. Some of those experiments worked. Real savings appeared in specific markets and specific service lines. The scale, however, remained modest relative to a $4 trillion system.
The cost curve bent. Then hospital consolidation, specialty drug launches, and administrative growth bent it back.
By the late 2010s, cost growth was accelerating again. Hospital systems that had merged through the prior decade began realizing the pricing power that consolidation provides. Specialty drug launches at prices previously unimaginable became routine. A workforce that had been strained before the pandemic became critically thin after it. Labor costs across health systems rose sharply. COVID-19 layered catastrophic disruption onto a system that was already under pressure.
The curve bent. Then the underlying forces of the American healthcare economy bent it back.
What Will It Actually Take to Fix Our Broken System
There is no single answer. Anyone offering one is selling something. But there is growing convergence among health economists, policy researchers, and clinicians about the directions that are both necessary and achievable, given sufficient sustained political will.
A few areas stand out:
Price transparency and reference pricing. Hospital price transparency rules, now on the books but inconsistently enforced, create the foundation for patients and employers to make informed decisions. Reference pricing, which sets a payment ceiling based on the cost of a high-quality lower-cost option, has shown genuine effects in California and other markets where it has been piloted.
Drug pricing negotiation at meaningful scale. The Inflation Reduction Act gave Medicare the authority to negotiate a small set of drug prices for the first time. That is a beginning. Expanding the scope of that authority, and potentially extending similar negotiating leverage to other payers, represents one of the highest-leverage interventions available given the trajectory of pharmaceutical spending.
Antitrust enforcement in healthcare markets. Decades of permissive merger review produced the regional hospital monopolies that now extract premium prices in markets across the country. Reversing that requires both stronger prospective review of future consolidation and, in some markets, structural remedies for consolidation already completed.
Reducing the administrative burden. Prior authorization reform, standardized credentialing processes, and reduced billing complexity could recover hundreds of billions annually from the system. This is politically difficult because the administrative layer employs large numbers of people and generates substantial revenue for certain parties. The waste is documented and real.
Artificial intelligence tools are beginning to show real promise in reducing administrative waste, flagging coding errors, and identifying patients at risk of costly complications before those complications arrive. Some health systems are already using AI to streamline prior authorization and reduce duplicative testing. Still, technology cannot negotiate drug prices, break up hospital monopolies, or simplify a Medicaid renewal process that fails people through policy choices, not missing software.
Value-based care at genuine scale. Moving the majority of healthcare payments away from fee-for-service and toward models that reward outcomes requires health systems with the scale to absorb risk, data infrastructure capable of measuring what matters, and payment designs sophisticated enough to reward prevention alongside treatment. This takes decades. It must begin in earnest.
Simplifying Medicaid and coverage renewal. The hairdresser in The Pitt should not be a cautionary tale. Continuous enrollment policies, automatic renewals that draw on existing data sources, and reduced paperwork burdens are achievable administrative reforms. They cost far less than the care that goes undelivered when coverage lapses unnecessarily.
Investing seriously in primary care. The United States dramatically underinvests in primary and preventive care relative to specialty services. The diabetic patient who left the ED against medical advice might never have reached a crisis requiring an ED visit if he had had consistent, affordable access to a primary care provider managing his condition over years.
None of this is simple. The healthcare sector represents roughly one-fifth of the American economy. Every dollar identified as waste is someone's revenue. Every proposed reform arrives with a constituency prepared to resist it. The lobbying resources arrayed against meaningful cost control in American healthcare are substantial, persistent, and sophisticated.
The cost of inaction is not abstract. It is a man walking out of an emergency department with an untreated diabetic crisis because he cannot afford to stay. It is a woman arriving in crisis because a Medicaid renewal form fell through cracks that a functioning system would never have left open.
The crisis is not hidden. It plays out in real emergency departments every day. The question is whether the collective will to address it can finally match the scale of what the problem requires.
Access, quality, and cost. For too long we have accepted that only two can coexist at any given time. Patients deserve all three.
The Prepared Patient newsletter is a companion to the forthcoming book The Prepared Patient: Your Guide to Surviving the Health Care System. Each issue explores the policies, economics, and realities that shape the care patients receive, and what patients can do to navigate the system more effectively. Statistical figures cited are drawn from CMS National Health Expenditure data, OECD health statistics, and peer-reviewed literature on healthcare price variation. The Pitt is a dramatic series; the patient scenarios described are fictional but reflect documented patterns in the literature on cost-related care avoidance and Medicaid enrollment churn.